REDUCING SOLVENT CONSUMPTION FOR LARGE-SCALE PEPTIDE API MANUFACTURING

Resembling a new era of innovative drug development, the interest of the biopharma industry in the peptide and oligonucleotide markets has risen significantly in the past five years. The advent of oral and inhaled peptide products has driven demand for these active pharmaceutical ingredients (APIs).Between 2018 and 2020, the average peptide manufacturing batch size increased by 2.3 times in response to a wider variety of peptide drug modalities entering the market. Furthermore, with the launch of new glucagon-like peptide (GLP) analogs targeting metabolic diseases like diabetes and obesity, there is a growing need for large-scale manufacturing of these APIs to treat a large patient population.Key Highlights:Innovative Green Chemistry: Discover how Bachem’s multi-column countercurrent solvent gradient purification (MCSGP) method significantly reduces solvent consumption and waste, making large-scale peptide API manufacturing more sustainable.Efficiency and Productivity Boost: Learn about the impressive improvements in throughput and productivity, with MCSGP reducing operation times from 5 days to just 24 hours compared to traditional batch chromatography.High Purity and Yield: Understand how Bachem achieves high purity (>99.3%) and yield in peptide production while minimizing environmental impact, showcasing their expertise in large-scale manufacturing. To download the entire resource, please complete the form.The post REDUCING SOLVENT CONSUMPTION FOR LARGE-SCALE PEPTIDE API MANUFACTURING appeared first on Bachem.Weiter zum vollständigen Artikel bei Bachem Holding AG Weiter zum vollständigen Artikel bei Bachem Holding AG